Fibroblast growth factors and their receptors in cancer (Q37895306)

24 August 2017

1 reference

title

Fibroblast growth factors and their receptors in cancer (English)

1 reference

24 August 2017

Kaisa Haglund

2

0 references

Jørgen Wesche

object named as

Jørgen Wesche

series ordinal

1

0 references

Ellen M Haugsten

series ordinal

3

object named as

Ellen Margrethe Haugsten

1 reference

PubMed ID

21711248

24 August 2017

language of work or name

English

0 references

publication date

1 July 2011

1 reference

24 August 2017

1 reference

24 August 2017

437

1 reference

24 August 2017

199-213

1 reference

24 August 2017

2

1 reference

24 August 2017

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genomic instability--an evolving hallmark of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Tumor cell metabolism: cancer's Achilles' heel

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Rules for making human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Cell signaling by receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The FGF family: biology, pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Roles for growth factors in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Patterns of somatic mutation in human cancer genomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Derailed endocytosis: an emerging feature of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

EMT, the cytoskeleton, and cancer cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor signalling: from development to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Structural and Functional Diversity in the FGf Receptor Multigene Family

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Insights into the molecular basis for fibroblast growth factor receptor autoinhibition and ligand-binding promiscuity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Receptor specificity of the fibroblast growth factor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Cellular signaling by fibroblast growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Sprouty, an intracellular inhibitor of Ras signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Sprouty proteins, masterminds of receptor tyrosine kinase signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Sprouty2 binds Grb2 at two different proline-rich regions, and the mechanism of ERK inhibition is independent of this interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Dusp6 (Mkp3) is a negative feedback regulator of FGF-stimulated ERK signaling during mouse development

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Sef inhibits fibroblast growth factor signaling by inhibiting FGFR1 tyrosine phosphorylation and subsequent ERK activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The transmembrane protein XFLRT3 forms a complex with FGF receptors and promotes FGF signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Regulated expression of FLRT genes implies a functional role in the regulation of FGF signalling during mouse development

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FRS2 alpha attenuates FGF receptor signaling by Grb2-mediated recruitment of the ubiquitin ligase Cbl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Ubiquitination of fibroblast growth factor receptor 1 is required for its intracellular sorting but not for its endocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Extended-synaptotagmin-2 mediates FGF receptor endocytosis and ERK activation in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Different intracellular trafficking of FGF1 endocytosed by the four homologous FGF receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Hrs regulates the endocytic sorting of the fibroblast growth factor receptor 2b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Spred2 interaction with the late endosomal protein NBR1 down-regulates fibroblast growth factor receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Keratinocyte growth factor receptor ligands target the receptor to different intracellular pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The binding of NCAM to FGFR1 induces a specific cellular response mediated by receptor trafficking

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factors, their receptors and signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The role of FGF/Erk signaling in pluripotent cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The landscape of somatic copy-number alteration across human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Drug-sensitive FGFR2 mutations in endometrial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Oncogenic role of fibroblast growth factor receptor 3 in tumorigenesis of urinary bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Somatic FGF9 mutations in colorectal and endometrial carcinomas associated with membranous beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGF receptor-4 (FGFR4) polymorphism acts as an activity switch of a membrane type 1 matrix metalloproteinase-FGFR4 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genome-wide association study identifies novel breast cancer susceptibility loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

8p11 myeloproliferative syndrome: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Comprehensive profiling of 8p11-12 amplification in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genomic and transcriptional aberrations linked to breast cancer pathophysiologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Defective lysosomal targeting of activated fibroblast growth factor receptor 3 in achondroplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Aberrant receptor internalization and enhanced FRS2-dependent signaling contribute to the transforming activity of the fibroblast growth factor receptor 2 IIIb C3 isoform

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Concomitant down-regulation of SPRY1 and SPRY2 in prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR4 transmembrane domain polymorphism and cancer risk: a meta-analysis including 8555 subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Terminal end bud maintenance in mammary gland is dependent upon FGFR2b signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Pleiotropic effects of FGFR1 on cell proliferation, survival, and migration in a 3D mammary epithelial cell model

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Inducible dimerization of FGFR1: development of a mouse model to analyze progressive transformation of the mammary gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Characterization of the recurrent 8p11-12 amplicon identifies PPAPDC1B, a phosphatase protein, as a new therapeutic target in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

A 1 Mb minimal amplicon at 8p11-12 in breast cancer identifies new candidate oncogenes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Triple-negative breast cancer: risk factors to potential targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Resistance to chemotherapy is associated with fibroblast growth factor receptor 4 up-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Lobular invasive carcinoma of the breast is a molecular entity distinct from luminal invasive ductal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Increased expression of fibroblast growth factor 8 in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Role of fibroblast growth factor 8 in growth and progression of hormonal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fgf10 is an oncogene activated by MMTV insertional mutagenesis in mouse mammary tumors and overexpressed in a subset of human breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Bladder cancer in 2010: how far have we come?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Urothelial tumorigenesis: a tale of divergent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The economic consequences of prostate and bladder cancer in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 3 mutation in voided urine is a useful diagnostic marker and significant indicator of tumor recurrence in non-muscle invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Therapeutic targeting of the prostate cancer microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The role of fibroblast growth factors and their receptors in prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Enhanced paracrine FGF10 expression promotes formation of multifocal prostate adenocarcinoma and an increase in epithelial androgen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGF8 over-expression in prostate cancer is associated with decreased patient survival and persists in androgen independent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Stromal activation associated with development of prostate cancer in prostate-targeted fibroblast growth factor 8b transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGF-8 is involved in bone metastasis of prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Inducible FGFR-1 activation leads to irreversible prostate adenocarcinoma and an epithelial-to-mesenchymal transition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Utilization of unlabeled probes for the detection of fibroblast growth factor receptor 2 exons 7 and 12 mutations in endometrial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Growth factors in the fetal and neonatal lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

A therapeutic target for smoking-associated lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: correlation with resistance to etoposide-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor 2-mediated translational control of IAPs blocks mitochondrial release of Smac/DIABLO and apoptosis in small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Mutation screening in patients with syndromic craniosynostoses indicates that a limited number of recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Molecular and cellular biology of rhabdomyosarcoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Gene expression profiling of human sarcomas: insights into sarcoma biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genome-wide identification of PAX3-FKHR binding sites in rhabdomyosarcoma reveals candidate target genes important for development and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Gene expression signatures identify rhabdomyosarcoma subtypes and detect a novel t(2;2)(q35;p23) translocation fusing PAX3 to NCOA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14)

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Generation of monoclonal antibody targeting fibroblast growth factor receptor 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

NF449 is a novel inhibitor of fibroblast growth factor receptor 3 (FGFR3) signaling active in chondrocytes and multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoma syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The kinase inhibitor TKI258 is active against the novel CUX1-FGFR1 fusion detected in a patient with T-lymphoblastic leukemia/lymphoma and t(7;8)(q22;p11).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FOP-FGFR1 tyrosine kinase, the product of a t(6;8) translocation, induces a fatal myeloproliferative disease in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The t(8;22) in chronic myeloid leukemia fuses BCR to FGFR1: transforming activity and specific inhibition of FGFR1 fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Indirubin-3'-monoxime inhibits autophosphorylation of FGFR1 and stimulates ERK1/2 activity via p38 MAPK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Phosphorylation of the SSBP2 and ABL proteins by the ZNF198-FGFR1 fusion kinase seen in atypical myeloproliferative disorders as revealed by phosphopeptide-specific MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGF5 as an oncogenic factor in human glioblastoma multiforme: autocrine and paracrine activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Identification of novel fibroblast growth factor receptor 3 gene mutations in actinic cheilitis and squamous cell carcinoma of the lip.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Smart drugs: tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

De-regulated FGF receptors as therapeutic targets in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Comparative pre-clinical evaluation of receptor tyrosine kinase inhibitors for the treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Development trends for monoclonal antibody cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

GP369, an FGFR2-IIIb-specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Differential expression of two fibroblast growth factor-receptor genes is associated with malignant progression in human astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Expression of fibroblast growth factor receptor-1 in human glioma and meningioma tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Basic fibroblast growth factor and fibroblast growth factor receptor I are implicated in the growth of human astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genetic analysis of human glioblastomas using a genomic microarray system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Detection of gene amplification and deletion in high-grade gliomas using a genome DNA microarray (GenoSensor Array 300).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor (FGFR) 4 correlated with the malignancy of human astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Gene amplification profiling of esophageal squamous cell carcinomas by DNA array CGH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Expression of fibroblast growth factor gene family and its receptor gene family in the human upper gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Growth inhibition by keratinocyte growth factor receptor of human salivary adenocarcinoma cells through induction of differentiation and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Overexpression of KLF13 and FGFR3 in oral cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Characterization of the malignant melanoma of soft-parts cell line GG-62 by expression analysis using DNA microarrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Overexpression of the fibroblast growth factor receptor 2-IIIc in Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Sp1-mediated transcriptional control of fibroblast growth factor receptor 4 in sarcomas of skeletal muscle lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Expression of fibroblast growth factor-2 and fibroblast growth factor receptor-1 in thyroid diseases: difference between neoplasms and hyperplastic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Identification of borderline thyroid tumors by gene expression array analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Prognostic impact of fibroblast growth factor 2 in non-small cell lung cancer: coexpression with VEGFR-3 and PDGF-B predicts poor survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Evidence for a role of FGF-2 and FGF receptors in the proliferation of non-small cell lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor-mediated signals contribute to the malignant phenotype of non-small cell lung cancer cells: therapeutic implications and synergism with epidermal growth factor receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Immunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Phenotypic differences of proliferating fibroblasts in the stroma of lung adenocarcinoma and normal bronchus tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Identification of novel gene amplifications in breast cancer and coexistence of gene amplification with an activating mutation of PIK3CA

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Expression of the FGFR1 gene in human breast-carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFRI andPLAT genes and DNA amplification at 8p 12 in breast and ovarian cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Molecular cytogenetic analysis of 11 new breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Integrated profiling of basal and luminal breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

CGH, cDNA and tissue microarray analyses implicate FGFR2 amplification in a small subset of breast tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Immunohistochemical detection of fibroblast growth factor receptor 3 in human breast cancer: correlation with clinicopathological/molecular parameters and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Amplification of fgfr4 gene in human breast and gynecological cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

IIIc isoform of fibroblast growth factor receptor 1 is overexpressed in human pancreatic cancer and enhances tumorigenicity of hamster ductal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Expression and functional activity of fibroblast growth factors and their receptors in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Enhanced expression of keratinocyte growth factor and its receptor correlates with venous invasion in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Characterization of keratinocyte growth factor and receptor expression in human pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR4 overexpression in pancreatic cancer is mediated by an intronic enhancer activated by HNF1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Up-regulation and co-expression of fibroblast growth factor receptors in human gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Alterations of chromosomal copy number during progression of diffuse‐type gastric carcinomas: metaphase‐ and array‐based comparative genomic hybridization analyses of multiple samples from individual tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR1 and WT1 are markers of human prostate cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Demonstration of fibroblast growth factor receptor-I in human prostate by polymerase chain reaction and immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Reciprocal relationship in gene expression between FGFR1 and FGFR3: implication for tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 3-IIIc mediates colorectal cancer growth and migration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genome-wide analysis of deoxyribonucleic acid in endometrial cancer using comparative genomic hybridization microarrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

High-resolution single nucleotide polymorphism array analysis of epithelial ovarian cancer reveals numerous microdeletions and amplifications

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Basic fibroblast growth factor and receptor expression in human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

cDNA array analysis of cytobrush-collected normal and malignant cervical epithelial cells: a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Activation of fibroblast growth factor receptor 3 and oncogene-induced senescence in skin tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Detection and follow-up of fibroblast growth factor receptor 3 expression on bone marrow and circulating plasma cells by flow cytometry in patients with t(4;14) multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Mutation, SNP, and isoform analysis of fibroblast growth factor receptor 3 (FGFR3) in 150 newly diagnosed multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

A molecular study of the t(4;14) in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Illegitimate switch recombinations are present in approximately half of primary myeloma tumors, but do not relate to known prognostic indicators or survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genomic alterations in blastic natural killer/extranodal natural killer-like T cell lymphoma with cutaneous involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Increased expression of fibroblast growth factor receptor 3 in CD34+ BCR-ABL+ cells from patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Hodgkin's lymphoma cell lines are characterized by frequent aberrations on chromosomes 2p and 9p including REL and JAK2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Modeling genomic diversity and tumor dependency in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Mutational analysis of the tyrosine kinome in colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Induction of chondrogenesis in neural crest cells by mutant fibroblast growth factor receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The genomic landscapes of human breast and colorectal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR2 mutations are rare across histologic subtypes of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The mutations in FGFR2-associated craniosynostoses are clustered in five structural elements of immunoglobulin-like domain III of the receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Apert syndrome mutations in fibroblast growth factor receptor 2 exhibit increased affinity for FGF ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 2, gain-of-function mutations, and tumourigenesis: investigating a potential link.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Mutations in different components of FGF signaling in LADD syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

A Molecular Brake in the Kinase Hinge Region Regulates the Activity of Receptor Tyrosine Kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Inferring the functional effects of mutation through clusters of mutations in homologous proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Integrated genetic and epigenetic analysis of bladder cancer reveals an additive diagnostic value of FGFR3 mutations and hypermethylation events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Recurrent and multiple bladder tumors show conserved expression profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The G1138A mutation rate in the fibroblast growth factor receptor 3 (FGFR3) gene is increased in cells carrying the t (4; 14) translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR3 dimer stabilization due to a single amino acid pathogenic mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Urothelial carcinoma following augmentation cystoplasty: an aggressive variant with distinct clinicopathological characteristics and molecular genetic alterations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Hypochondroplasia and Acanthosis nigricans: a new syndrome due to the p.Lys650Thr mutation in the fibroblast growth factor receptor 3 gene?

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR4 Gly388Arg polymorphism contributes to prostate cancer development and progression: a meta-analysis of 2618 cases and 2305 controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Polymorphisms of fibroblast growth factor receptor 4 have association with the development of prostate cancer and benign prostatic hyperplasia and the progression of prostate cancer in a Japanese population

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Association of FGFR4 genetic polymorphisms with prostate cancer risk and prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 1 is fused to FIM in stem-cell myeloproliferative disorder with t(8;13)

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The t(8;13)(p11;q11-12) rearrangement associated with an atypical myeloproliferative disorder fuses the fibroblast growth factor receptor 1 gene to a novel gene RAMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fibroblast growth factor receptor 1 oncogene partner as a novel prognostic biomarker and therapeutic target for lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Clinical variability of patients with the t(6;8)(q27;p12) and FGFR1OP-FGFR1 fusion: two further cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Identification of four new translocations involving FGFR1 in myeloid disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

8p12 stem cell myeloproliferative disorder: the FOP-fibroblast growth factor receptor 1 fusion protein of the t(6;8) translocation induces cell survival mediated by mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt/mTOR pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

8p11 myeloproliferative syndrome preceded by t(8;9)(p11;q33), CEP110/FGFR1 fusion transcript: morphologic, molecular, and cytogenetic characterization of myeloid neoplasms associated with eosinophilia and FGFR1 abnormality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

A biphenotypic transformation of 8p11 myeloproliferative syndrome with CEP1/FGFR1 fusion gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Common features of myeloproliferative disorders with t(8;9)(p12;q33) and CEP110-FGFR1 fusion: report of a new case and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Fusion of the BCR and the fibroblast growth factor receptor-1 (FGFR1) genes as a result of t(8;22)(p11;q11) in a myeloproliferative disorder: the first fusion gene involving BCR but not ABL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

LRRFIP1, a new FGFR1 partner gene associated with 8p11 myeloproliferative syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Identification of a novel gene, FGFR1OP2, fused to FGFR1 in 8p11 myeloproliferative syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

8p11 myeloproliferative syndrome with a novel t(7;8) translocation leading to fusion of the FGFR1 and TIF1 genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The t(1;9)(p34;q34) and t(8;12)(p11;q15) fuse pre-mRNA processing proteins SFPQ (PSF) and CPSF6 to ABL and FGFR1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Endogenous retroviral sequence is fused to FGFR1 kinase in the 8p12 stem-cell myeloproliferative disorder with t(8;19)(p12;q13.3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

High-resolution array CGH analysis of salivary gland tumors reveals fusion and amplification of the FGFR1 and PLAG1 genes in ring chromosomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

Functional FGFR4 Gly388Arg Polymorphism Predicts Prognosis in Lung Adenocarcinoma Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

8p11 myeloproliferative syndrome with BCR-FGFR1 rearrangement presenting with T-lymphoblastic lymphoma and bone marrow stromal cell proliferation: A case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

The expression of basic fibroblast growth factor (bFGF) in tumor-associated stromal cells and vessels is inversely correlated with non-small cell lung cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBJ20101603

21 January 2018

Identifiers

DOI

10.1042/BJ20101603

1 reference

24 August 2017

1 reference

PubMed ID

21711248